MeSH D008258 - waldenstrom macroglobulinemia
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Alembic Pharmaceuticals | Cyclophosphamide | Cyclophosphamide | 2022-11-10 | |||
| Amneal Pharmaceuticals | Cyclophosphamide | Cyclophosphamide | 2018-05-25 | |||
| ANI Pharmaceuticals | Cyclophosphamide | Cyclophosphamide | 2018-03-19 | |||
| Baxter | Cyclophosphamide | Cyclophosphamide | 2008-05-21 | |||
| Cyclophosphamide | Cytoxan | 1982-01-01 | ||||
| Cyclophosphamide | Cytoxan (lyophilized) | 1982-01-01 | ||||
| Beigene | Zanubrutinib | Brukinsa | 2021-11-22 | |||
| Bristol Myers Squibb | Thalidomide | Thalidomide BMS (previously Thalidomide Celgene) | 2008-04-16 | |||
| Thalidomide | Thalomid | 2023-12-09 | 1998-07-16 | |||
| Cipla | Cyclophosphamide | Cyclophosphamide | 2019-01-18 | |||
| Dr Reddys Laboratories | Cyclophosphamide | Cyclophosphamide | 2035-07-13 | 2023-06-07 | ||
| Eugia Pharma Specialties | Cyclophosphamide | Cyclophosphamide | 2035-06-26 | 2021-08-25 | ||
| Hikma Pharmaceuticals | Cyclophosphamide | Cyclophosphamide | 2013-09-16 |
1
2
3
>
Clinical Trials
Historical Success Rate
Phase 1
74%73/99
Phase 2
24%25/106
Phase 3
37%11/30
Approved: 5Overall Success rate: 6%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
>
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use